Michael Katlan, MD
Allergy · Albany, NYNPI 1427059245
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,965 of the $90,762 with a category attached, or 85.9%. AstraZeneca accounts for 78.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $28,376 and has fallen 56.1% since, to $12,446 in 2025. Among allergy clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $449.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71K
- Boehringer Ingelheim$12K
- Genentech USA, Inc.$4K
- Grifols USA, LLC$2K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$389
- plus $417 from 4 others
What the payments were for
- Consulting fees$3,8114%
- Speaking & faculty fees$77,96586%
- Travel & lodging$4,0134%
- Food & beverage$4,9455%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 145 | $70,762 |
| Boehringer Ingelheim | 21 | $12,053 |
| Genentech USA, Inc. | 9 | $3,755 |
| Grifols USA, LLC | 4 | $1,737 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,649 |
| GSK | 11 | $389 |
| Sanofi | 6 | $343 |
| Novartis | 2 | $39 |
| Amgen | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,762 in reported general payments places this provider in the 90th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 29 | $139,052 |
| Fasenra PenBenralizumab | 21 | $116,801 |
| Advair HfaFluticasone Propion/Salmeterol | 116 | $74,335 |
| Breo ElliptaFluticasone/Vilanterol | 96 | $62,803 |
| Spiriva RespimatTiotropium Bromide | 64 | $60,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $44,157 |
| XolairOmalizumab | 18 | $44,054 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 143 | $23,805 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 75 | $18,565 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $17,967 |
| Epinephrine | 88 | $16,063 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $15,749 |
| Fluticasone Propionate HfaFluticasone Propionate | 44 | $14,857 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 308 | $14,362 |
| Pulmicort FlexhalerBudesonide | 16 | $11,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $389 | $124,682177 claims |
| Boehringer IngelheimSpiriva Respimat | $12,053 | $60,27164 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $70,762 | $44,96864 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 allergy providers in New York.
Other allergy in Albany
- Scott OsurAlbany$11K
- Janet ClaassenAlbany$1K
- Thomas FlaimAlbany$1K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.